Researchers analyzed data on three variants of concern and found that viral loads were higher and infection lasted longer for the B.1.1.7 variant. They all were more infectious than the original strain, and transmissibility also depended on population demographics.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved since it first emerged in late 2019. Several mutations of the virus have since been observed, with some variants appearing more infectious than the original strain, which also appear to evade immunity gained by previous infections.
Some of these variants have been labeled as variants of concern (VOC) because of their greater transmissibility and infectiousness. These have also been associated with second and third waves in the infections in many countries, leading to their close monitoring, either by sequencing the complete viral genome or reverse-transcription polymerase chain reaction (RT-PCR).
Some RT-PCR studies have suggested that the VOCs may be causing higher viral loads, but those studies were done only at one-time point. In a new study published on the medRxiv* preprint server, researchers from France report how different variants affect virus kinetics in infections.
Testing virus loads
The researchers used data from RT-PCR tests specific to variants performed between February and April 2021 on SARS-CoV-2 positive samples. They used data from more than 17,000 samples. About 73% of the samples were of the B.1.1.7 variant, 6% of the B.1.351 or P.1 variants, and the rest were wild-type.
A model was developed that included several co-factors, such as the patient’s age, the virus lineage, and whether the patient was hospitalized.
They found that the viral loads were different between the wild-type virus and the different variants. For the B.1.1.7 strain, peak virus load increased with age. The cycle threshold values for the B.1.351 and P.1 strains were slightly lower than that for the wild-type strain, indicating slightly lower viral loads for these variants.
In addition, the rate of decrease of viral load with time was lower for the B.1.1.7 strain compared to the wild-type virus. The data also showed higher peak loads and a lower rate of viral load decrease in hospitalized individuals, about 1.5 days more.
When covid-19 struck Europe in March 2020, hospitals were plunged into a health crisis that was still badly understood. “Doctors really didn’t have a clue how to manage these patients,” says Laure Wynants, an [...]
Pfizer found to be 88 per cent effective at preventing symptomatic disease from delta variant. Two doses of Pfizer-BioNTech or AstraZeneca-Oxford's COVID-19 vaccines are nearly as effective against the highly transmissible delta coronavirus variant [...]
South African pharmaceutical company Aspen said Monday it was releasing its first batch of African-produced COVID-19 vaccines under a licensing deal with the US giant Johnson & Johnson. The Durban-based company said the first [...]
Since the coronavirus pandemic shut down the world, scientists have clamored to develop vaccines to prevent the spread and medicines that will cure the sick. But a virus’ main goal is to replicate and [...]
The highly transmissible delta variant of SARS-CoV-2, the coronavirus causing the disease COVID-19, is now present in 124 countries and will become the dominant strain globally in the coming months as it is outcompeting [...]
Scientists have backed proposals for Covid boosters in the autumn after blood tests on hundreds of people revealed that protective antibodies can wane substantially within weeks of second vaccine shots being given. Falls in [...]
Researchers in the United States have conducted a study showing that the coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna generate a coordinated adaptive immune response that is capable of eliciting recall [...]
CSIRO, Australia's national science agency, played an important role in evaluating heat-tolerant COVID-19 vaccine formulations developed by the Indian Institute of Science (IISc) and biotech start-up Mynvax—against all current SARS-CoV-2 variants of concern. Published [...]
Podcast – Nanovisaging 2040 How Synergies between Nanotechnology, Nanomedicine, and AI might Benefit Humanity
Frank Boehm (NanoApps Medical Inc. Founder) in discussion with Nana Kay in a Wealth Secrets podcast. EP 19. Nanovisaging 2040. From Nana Kay: Nanovisaging 2040: How Synergies between Nanotechnology, Nanomedicine, and AI might Benefit [...]
Canada, like several other countries, has been mixing and matching COVID-19 vaccines for weeks amid safety concerns over the AstraZeneca shot. On Monday, the chief scientist at the World Health Organization (WHO) cautioned against that approach, calling [...]
Scientists have harnessed CRISPR gene-editing technology to block the replication of the novel coronavirus in human cells — an approach that could one day serve as a new treatment for COVID-19. However, the study was performed [...]
A recent study by scientists from Japanese universities has shown that the shape of cell-derived nanoparticles, known as "extracellular vesicles" (EVs), in body fluids could be a biomarker for identifying types of cancer. In [...]
An important lesson for vaccine design Australian scientists researching how our immune system responds to COVID-19 have revealed that those infected by early variants in 2020 produced sustained antibodies, however, these antibodies are not [...]
1. How COVID-19 is affecting the globe Confirmed cases of COVID-19 have passed 185 million globally, according to Johns Hopkins University. The number of confirmed deaths stands at more than 4 million. More than 3.29 [...]
The World Health Organization (WHO) has added another COVID strain to its list of coronavirus variants to keep an eye on: the COVID-19 Lambda variant. This particular variant has now spread to more than two dozen [...]